Intracerebroventricular infusion of nerve growth factor induces pain-like response in rats.
New strategies have recently been developed where infusion of neurotrophic factors into the brain can rescue different neuronal populations. However, negative side effects have been observed in clinical trials infusing nerve growth factor (NGF) into the lateral ventricle in man, namely pain. Little is known about pain behavior in animals after intracerebroventricular (i.c.v.) neurotrophic injections. Thus, we have examined the effects of i.c.v. infusion of NGF for 2 weeks on the behavioral response of rats to mechanical, cold and heat stimulation. Seven micrograms/day of NGF elicited a significant decrease in vocalization threshold to mechanical stimulation and a significantly increased response to cold and heat stimuli as compared with control. The concentration of NGF in cerebrospinal fluid (CSF) was significantly increased as compared with non-allodynic rats. The enhanced responses to mechanical and heat, but not to cold, stimulation were significantly reduced by CP-99994, a selective antagonist to tachykinin NK-1 receptors. When NGF was infused into the brain parenchyma (striatum, cortex and septum) no allodynic nor hyperalgesic responses could be detected. These results indicate that in rats i.c.v. but not intraparenchymal infusion of NGF induce mechanical and cold allodynia as well as heat hyperalgesia, which is mediated, at least in part, by activation of NK-1 receptors.
Hao
J
J
Department of Medical Laboratory Sciences and Technology, Division of Clinical Neurophysiology, Karolinska Institute, Huddinge University Hospital, Huddinge, Sweden.
Ebendal
T
T
Xu
X
X
Wiesenfeld-Hallin
Z
Z
Eriksdotter Jönhagen
M
M
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D001921:Brain / Q000502:physiology*; D003080:Cold Temperature; D006358:Hot Temperature; D006941:Hyperesthesia / Q000134:cerebrospinal fluid; D007276:Injections, Intraventricular; D008297:Male; D020932:Nerve Growth Factor / Q000134:cerebrospinal fluid / Q000494:pharmacology*; D064729:Neurokinin-1 Receptor Antagonists; D010146:Pain / Q000503:physiopathology / Q000523:psychology*; D017288:Pain Threshold / Q000187:drug effects; D010812:Physical Stimulation; D010880:Piperidines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D012016:Reference Values; D014828:Vocalization, Animal
D064729:Neurokinin-1 Receptor Antagonists; D010880:Piperidines; C080755:3-(2-methoxybenzylamino)-2-phenylpiperidine; D020932:Nerve Growth Factor